Literature DB >> 17686967

Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.

Lian Wei1, Charles W Locuson, Timothy S Tracy.   

Abstract

CYP2C9 catalyzes the demethylation of the biphasic kinetics substrate (S)-naproxen, and the CYP2C9*2 (R144C) and CYP2C9*3 (I359L) variants are associated with lower rates of (S)-naproxen demethylation. To assess the reasons for these reductions in catalytic activity of the two variants and potential substrate concentration-dependent differences in a biphasic kinetics substrate, cytochrome P450 (P450) cycle coupling and uncoupling were monitored during coincubation of (S)-naproxen and CYP2C9 over a range of P450 reductase concentrations. Coupling was greatest in the CYP2C9.1 enzyme, followed by CYP2C9.2, and then CYP2C9.3. Uncoupling in CYP2C9.1 and CYP2C9.3 was primarily to H(2)O(2). In contrast, CYP2C9.2 uncoupled to excess water preferentially. The conversion of enzyme to the high spin state was similar in CYP2C9.1 and CYP2C9.2, but lower in CYP2C9.3. It is noteworthy that neither altered substrate binding nor altered interaction with reductase seemed to be involved in reduced catalysis. These results suggest that in addition to coupling differences, differential uncoupling to shunt products and differences in spin state help explain the reduced catalytic activity in these enzymes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686967     DOI: 10.1124/mol.107.036178

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.

Authors:  Y Liu; H Jeong; H Takahashi; K Drozda; S R Patel; N L Shapiro; E A Nutescu; L H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

2.  Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.

Authors:  Makiko Kusama; Kazuya Maeda; Koji Chiba; Akinori Aoyama; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2008-12-12       Impact factor: 4.200

3.  Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.

Authors:  Matthew A Hummel; Peter M Gannett; Jarrett Aguilar; Timothy S Tracy
Journal:  Arch Biochem Biophys       Date:  2008-05-01       Impact factor: 4.013

4.  Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk.

Authors:  Simone P Pinheiro; Margaret A Gates; Immaculata De Vivo; Bernard A Rosner; Shelley S Tworoger; Linda Titus-Ernstoff; Susan E Hankinson; Daniel W Cramer
Journal:  Int J Mol Epidemiol Genet       Date:  2010-09-03

Review 5.  A novel type of allosteric regulation: functional cooperativity in monomeric proteins.

Authors:  Ilia G Denisov; Stephen G Sligar
Journal:  Arch Biochem Biophys       Date:  2012-01-08       Impact factor: 4.013

6.  Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis-Type (Atypical) Enzyme Kinetics.

Authors:  Eleanore Seibert; Timothy S Tracy
Journal:  Methods Mol Biol       Date:  2021

7.  Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Authors:  Darcy R Flora; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2011-12-28       Impact factor: 3.922

Review 8.  Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.

Authors:  Larisa H Cavallari; Jaekyu Shin; Minoli A Perera
Journal:  Pharmacotherapy       Date:  2011-12       Impact factor: 4.705

9.  Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.

Authors:  Chris D Bostick; Katherine M Hickey; Lance A Wollenberg; Darcy R Flora; Timothy S Tracy; Peter M Gannett
Journal:  Drug Metab Dispos       Date:  2016-03-09       Impact factor: 3.922

10.  Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.

Authors:  Sonia J Parikh; Chiara M Evans; Juliet O Obi; Qinghai Zhang; Keiko Maekawa; Karen C Glass; Manish B Shah
Journal:  Mol Pharmacol       Date:  2020-09-16       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.